Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
|ClinicalTrials.gov Identifier: NCT01217255|
Recruitment Status : Completed
First Posted : October 8, 2010
Last Update Posted : December 19, 2013
Because of high cost, persons with hemophilia in many developing countries cannot afford adequate treatment. For example, many persons with hemophilia in India and China are only rarely treated with factor replacement in response to bleeds, and as a result many have developed significant arthropathy and disability. A pilot study in China estimated the mean Hemophilia Joint Health Score (HJHS) at 13.1 (SD 9.03) suggesting that these children had highly prevalent, severe joint disease. The lack of relationship between the HJHS and treatment history suggests overall inadequate therapy.
The proposed study will quantify the burden of arthropathy, physical disability, and quality of life (QoL) in boys with hemophilia in Brazil - where comprehensive treatment is just beginning to be widely available. This study will also provide an opportunity to compare these outcomes to those observed in Canada, where the dominant therapy has become life-long prophylaxis.
|Condition or disease|
|Hemophilia A Hemophilia B|
In order to quantify the burden of illness in hemophilia, and to study the response to different treatments, it is necessary to have quantitative outcome measures of high validity and reliability. The International Prophylaxis Study Group (IPSG - chair Dr. Victor Blanchette) was established in 2001 with the stated purpose of developing and testing outcome tools for this purpose. The group has developed a magnetic resonance imaging (MRI) score for quantifying arthropathy (representing the domain of structure and function domain in the ICF framework), a quantitative physical examination score, and the Hemophilia Joint Health Score or HJHS, to replace the older and less sensitive World Federation of Hemophilia (WFH) score (representing the domain of structure and function in the ICF). In addition Canadian investigators have also developed a quality of life measure for boys with hemophilia, the Canadian Hemophilia Outcomes Kids' Life Assessment Tool or CHO-KLAT (representing the domain of participation in the ICF).
We will use these tools, and other validated measures, to begin to determine the burden of hemophilia in Brazil and compare it to the burden of disease in Canada. Additionally, we will use this study to demonstrate the validity of these tools in the Brazilian population.
|Study Type :||Observational|
|Actual Enrollment :||100 participants|
|Official Title:||Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World: The Sao Paulo - Toronto Hemophilia Study|
|Study Start Date :||September 2010|
|Actual Primary Completion Date :||October 2013|
|Actual Study Completion Date :||October 2013|
Subject's will be recruited from the Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paolo (HCFMUSP); Universidade Estadual de Campinas (UNICAMP); Universidade Federal de São Paulo (UNIFESP)
Recruited from The Hospital for Sick Children
- Burden of Illness [ Time Frame: 3 years ]
Burden of disability for Brazilian and Canadian children will be be determined by analysis of the following domains:
Structure and Function Domain (HJHS score, Biometrics,Radiographs) Activity Domain (ASK and FISH scales) Participation Domain (CHO-KLAT and PedsQL Quality of Life Questionnaire) Health Condition Domain (bleeding frequency) Personal Factors Domain (Ethnicity, level of education of parent/guardian, habitual exercise) Environmental Domain (Household income of parent/guardian)
- The Activity Scale for Kids (ASK) [ Time Frame: Day 1 ]Children's self-reported activities will be measured with the Activity Scales for Kids (ASK) as part of the Activity Domain
- Functional Independence Scale for Hemophilia (FISH) [ Time Frame: Day 1 ]
Observed activity limitations will be measured with the FISH as part of the Activity Domain.
The FISH has been validated for use in developing countries. It consists of observed activities of daily living that are scored for quality.
- Hemophilia Joint Health Score (HJHS) [ Time Frame: Day 1 ]
The HJHS is a valid and reliable scored measure of joint structural limitations as applied to the index joints.
This score will be a measure of the Structure and function domain.
- Radiographs [ Time Frame: Day 1 ]Radiographs will be taken of all 6 index joints. This will be done as part of the structure and function domain.
- Canadian Haemophilia Outcomes - Kids Life Assessment Tool (CHO-KLAT) [ Time Frame: Day 1 ]After the completion of the pre-study cultural validation of the Brazilian translation of the CHO-KLAT scale, we will use it as a Quality of Life tool to measure the Participation domain
- Bleeding Frequency [ Time Frame: Day 1 ]Families will be interviewed to determine bleeding frequency in the last 6 months. This factor will be incorporated into the Health condition domain.
- Biometrics [ Time Frame: Days 1 ]The height and weight will be compared to national nomograms.
- Personal Factors [ Time Frame: Day 1 ]Ethnicity, level of education of the parent-guardian will be self-reported.
- Environmental domain [ Time Frame: Day 1 ]Whether a subject lives in a rural or urban area and household income will be recorded.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01217255
|Universidade Estadual de Campinas, UNICAMP|
|Campinas, Sao Paulo, Brazil|
|Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo|
|Sao Paolo, Brazil|
|Universidade Federal de São Paulo (UNIFESP)|
|Sao Paulo, Brazil|
|The Hospital for Sick Children|
|Toronto, Ontario, Canada, M5G 1X8|
|Principal Investigator:||Brain M. Feldman, MD,MSc,FRCPC||The Hospital for Sick Children|